FLGR242

updated

FLGR242 is a seller's name for a claimed follistatin fragment joined by a linker to an albumin-binding element, with no independently confirmed identity. It is sold for muscle by blocking myostatin, with a claimed 19-day half-life. No animal or human study of it was found, no test shows it blocks myostatin, its mass and albumin binding are the seller's own figures, and results for other follistatin products do not transfer to it. Graded F because its full identity is unresolved and no independent study has given it to animals or people.

seller-described follistatin-albumin construct

  • Complete construct not independently disclosed
  • About 40 kDa and below-20 nM albumin affinity are seller claims
  • The 19-day persistence figure is a seller claim
  • No independent administration study appears in the cited public records

What exactly is FLGR242?

Sellers do not provide a reproducible complete identity. One seller describes a follistatin fragment, glycine-serine linker, and albumin-binding element, but does not supply the complete construct and independent analytical package needed to establish identity.

  • Sequence: complete termini, linker, albumin-binding element, modifications, and glycosylation state.
  • Structure: independent intact mass, peptide mapping, disulfide and fold characterization, and aggregation.
  • Function: target, off-target, albumin-binding, and myostatin or activin bioactivity on the named material.
  • Parenteral quality: content, sterility, endotoxin, particles, stability, and container-level release data.

source: Seller page · partial construct claims, BioLongevity Research.

source: PubMed · no independent FLGR242 paper, PubMed records.

source: US20260008820A1 · generic platform, no FLGR242, US Patent Application US20260008820A1.

Has FLGR242 been administered in animals or people?

The cited public records contain no independent FLGR242 animal or human administration study. They provide no studied dose, route, interval, clinical outcome, or adverse-event denominator.

Does the 40 kDa figure prove identity?

An approximate seller-listed mass cannot reveal the full sequence, modification state, correct fold, aggregates, binding, or functional potency.

source: Seller page · partial construct claims

source: PubMed · no independent FLGR242 paper

source: ClinicalTrials.gov · no FLGR242 human study, ClinicalTrials.gov search for "FLGR242" and its spacing variant, run on 8 September 2026.

Does FLGR242 inhibit myostatin?

No FLGR242-specific myostatin inhibition has been demonstrated. The cited patent describes a generic albumin-binding platform and does not name or test FLGR242; results for natural follistatin, FST315, FST288, or AAV-FS344 do not apply to it.

source: US20260008820A1 · generic platform, no FLGR242

source: Seller page · partial construct claims

source: PubMed · no independent FLGR242 paper

What is known about safety?

The cited public records contain no compound-specific safety data. Identity, exposure, immune response, broad activin-family effects, fertility, vascular and tumor biology, pregnancy, interactions, and sterile-product quality are unresolved.

Does a lyophilized vial establish an injectable route?

A lyophilized vial and bacteriostatic-water presentation do not establish a studied route, dose, sterility, or injection safety.

source: Seller page · 19-day persistence claim, BioLongevity Labs.

source: PubMed · no independent FLGR242 paper

source: ClinicalTrials.gov · no FLGR242 human study

source: Seller page · partial construct claims

Does FLGR242 have a 19-day half-life or an approval?

The cited U.S. records contain no compound-specific pharmacokinetic curve or exact-name approval entry. The 19-day figure is a seller claim. WADA’s S0 category prohibits non-approved substances, and the claimed myostatin-modulating action may also fall under S4.3 if confirmed.

source: Seller page · 19-day persistence claim

source: openFDA · no exact-name approval record, openFDA Drugs@FDA search for the generic name FLGR242, with the hyphenated spelling, run on 8 September 2026.

source: WADA 2026 · status depends on actual identity, World Anti-Doping Agency, effective 1 January 2026.

Studies and sources

US20260008820A1 · generic platform, no FLGR242

Patent application

US Patent Application US20260008820A1.

The application describes a broad glycopeptide albumin-binding platform. The patent does not name FLGR242, disclose an FLGR242 sequence, identify an FLGR242 test article, or report FLGR242 pharmacokinetics.

Study design
Applicant-written platform disclosure

It cannot fill the compound-specific identity gap.

Read the original source
Seller page · partial construct claims

Commercial product page

BioLongevity Research.

The seller describes a follistatin fragment connected through a glycine-serine linker to an albumin-binding element, about 40 kDa mass, below-20 nM albumin affinity, and a 10 mg lyophilized presentation. It does not publish an independent complete sequence, analytical map, or validation study.

Study design
Seller-authored product description
Funding
Seller

Useful only for documenting what is marketed.

Read the original source
Seller page · 19-day persistence claim

Commercial product page

BioLongevity Labs.

The seller markets 2 mg FLGR242 in a B-vitamin blend and claims serum persistence of about 19 days. It provides no compound-specific concentration-time curve or independent pharmacokinetic report. A vial and bacteriostatic-water presentation do not establish a studied route.

Study design
Seller-authored product description
Funding
Seller
Read the original source
WADA 2026 · status depends on actual identity

Sports rule

World Anti-Doping Agency, effective 1 January 2026.

S0 prohibits non-approved pharmacological substances, and S4.3 prohibits myostatin-function modifiers. Which provision applies to FLGR242 depends on establishing what the product actually is and does.

Study design
Binding sport rule for covered athletes
Read the original source

Why is FLGR242 in F tier?

The F grade reflects an unresolved molecular identity and the absence of an independent administration study in the cited public records. Seller specifications do not provide a complete sequence, analytical identity, pharmacology, or pharmacokinetics.

how tiers are graded: methodology · every cited source · about reptides.

Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.